"NxStage is represented by 11 accepted abstracts evaluating home hemodialysis, treatment frequency, and peritoneal dialysis," said
The collection of data will be presented at the
Two oral presentations confirm findings from previously published interim analyses of the FREEDOM study of daily home hemodialysis: specifically, that frequent home hemodialysis coincided with dramatic reductions in post-treatment recovery time and broad improvements in both physical and mental health-related quality of life. Another abstract finds that nocturnal home hemodialysis is associated with greater retention of home hemodialysis patients compared to daytime treatment. Four other oral presentations will also address aspects of home hemodialysis and hemodialysis frequency.
"Data continues to affirm the benefits of frequent home hemodialysis by showing continued improvements in patient-centered outcomes," said, Dr.
Five posters will also be presented, including data that demonstrate higher home hemodialysis training graduation rates in patients using the Nx2me Connected Health® iPad® application.
Oral presentations will be made by experts in the industry on both
Full abstracts can be read online at https://www.asn-online.org/abstracts/.
Conference attendees can also meet with NxStage representatives in booth 1127 to discuss the most recent publications.
Visit www.NxStage.com for more information about therapy options with the NxStage® System One™.
The NxStage System One is a prescription device and, like all medical devices, involves some risks. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream, and blood loss due to clotting or accidental disconnection of the blood tubing set. Patients should consult with their doctor to understand the risks and responsibilities of home and/or more frequent hemodialysis using the NxStage System One. Additionally, the reported benefits of home and/or more frequent hemodialysis may not be experienced by all patients. Patients and providers are encouraged to contact their state regulators to discuss state-specific regulations that may impact dialysis in the skilled nursing facility setting.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the
About NxStage Medical
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the
View original content with multimedia:http://www.prnewswire.com/news-releases/eleven-unique-nxstage-abstracts-accepted-for-2017-kidney-week-300547757.html
News Provided by Acquire Media